Drug

Ceftaroline fosamil

Established medicine

ClassBacterial penicillin-binding protein inhibitorResearchOngoing clinical research

Also known as Teflaro, Ceftarolina fosamilo, Ceftarolinum fosamilum.

RxNorm1040004 ChEMBLCHEMBL501122 ATCJ01DI02UNII7P6FQA5D21

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study

Clinical trial2026-06-03Results expected Q4 2027 · ClinicalTrials.gov

Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

Clinical trial2021-11-02Results posted · ClinicalTrials.gov

Open-label, Multicentre Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ceftaroline In Neonates And Young Infants With Late-onset Sepsis

Clinical trial2017-12-26Terminated · ClinicalTrials.gov

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities

Clinical trial2017-09-06Results posted · ClinicalTrials.gov

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftaroline in Patients With CSF Device

Clinical trial2016-10-24Completed · ClinicalTrials.gov

A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus

Clinical trial2016-02-01Results posted · ClinicalTrials.gov

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.

Clinical trial2015-01-01Terminated · ClinicalTrials.gov

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)

Clinical trial2014-08-01Completed · ClinicalTrials.gov

A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Clinical trial2014-07-01Completed · ClinicalTrials.gov

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization

Clinical trial2014-07-01Completed · ClinicalTrials.gov

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Clinical trial2014-07-01Completed · ClinicalTrials.gov

Approval: Zinforo (EMA)

Regulatory2012-08-22EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ceftaroline fosamil

Aliases & brands

TeflaroCeftarolina fosamiloCeftarolinum fosamilum

RxNorm CUI

1040004

ChEMBL ID

CHEMBL501122

ATC codes

J01DI02

UNII

7P6FQA5D21

Primary mechanism

Bacterial penicillin-binding protein inhibitor

Regulatory jurisdictions

ema

Pharmacology & targets

9 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

D-alanyl-D-alanine carboxypeptidase DacB

dacB · P24228